ACRES Launches Outreach and Education Blog
The ACRES' Accountable Research Blog is being piloted in the San Antonio, Texas market, and is projected to be extended to other Hearst media markets, both domestically and internationally.
The Alliance for Clinical Research Excellence and Safety (ACRES) and Texas-based for-profit San Antonio Express-News, an affiliate of Hearst Communications, have formed a strategic alliance to create a blog as a vehicle for public outreach and education across the healthcare and clinical research endeavor. The blog is directed toward patients and the public. The ACRES' Accountable Research Blog is being piloted in the San Antonio, Texas market, and is projected to be extended to other Hearst media markets, both domestically and internationally. In addition, the alliance partners will work together to develop and use the blog to conduct surveys on important research issues, to gather public feedback and provide educational blog opportunities to stakeholders in healthcare and biomedical research.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
